Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations.

ABSTRACT: Vaccine efficacy determined within the controlled environment of a clinical trial is usually substantially greater than real-world vaccine effectiveness. Typically, this results from reduced protection of immunologically vulnerable populations, such as children, elderly individuals and people with chronic comorbidities. Consequently, these high-risk groups are frequently recommended tailored immunisation schedules to boost responses. In addition, diverse groups of healthy adults may also be variably protected by the same vaccine regimen. Current population-based vaccination strategies that consider basic clinical parameters offer a glimpse into what may be achievable if more nuanced aspects of the immune response are considered in vaccine design. To date, vaccine development has been large

SUBMITTER: Purcell RA 

PROVIDER: S-EPMC10433199 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature